Clinical Trial

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-12-23; most recent amendment 2022-10-18.
Status change: Enrolling by Invitation → Active, Not Recruiting 2022-10-18
Status change: Recruiting → Enrolling by Invitation 2021-11-12
Status change: Not Yet Recruiting → Recruiting 2021-06-29
Trial Details
NCT Number NCT04687020
Lead Sponsor NS Pharma, Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 9 participants
Start Date 2021-06-10
Primary Completion 2032-09 (estimated)
Study Completion 2032-10 (estimated)
Updated on ClinicalTrials.gov 2022-10-19